Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361 859 recipients

被引：192

作者：

Friedman, Gary D. ^{[1
,2
]}

Flick, E. Dawn ^{[2
]}

Udaltsova, Natalia ^{[2
]}

Chan, James ^{[3
]}

Quesenberry, Charles P., Jr. ^{[2
]}

Habel, Laurel A. ^{[2
]}

机构：

[1] Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA

[2] Kaiser Permanente Med Care Program, Div Res, Oakland, CA 94611 USA

[3] Kaiser Permanente Med Care Program, Pharm Outcomes Res Grp, Oakland, CA USA

来源：

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2008年 / 17卷 / 01期

关键词：

statins; neoplasms; pharmacoepidemiology;

D O I：

10.1002/pds.1507

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Purpose Determine the risk of cancer in statin users. Methods Risk of cancer in up to 9.4 years after first recorded receipt of statins was evaluated in subscribers of an integrated health care program in northern California. Statin use and cancer development were ascertained from the program's pharmacy records and cancer registry from August 1994 to December 2003. Results Most of the 361859 statin users received lovastatin, simvastatin or both. Results are presented from analyses with 2-year lag and use for over 5 years. Most of the observed associations were likely due to chance or confounding. The few associations that seemed less readily explainable were increased risk of cancers of the thyroid, esophagus and urinary tract and decreased risk of colon cancer in men. Increased risk of lung cancer was the only nominally statistically significant positive association in women and could be partially attributable to their smoking habits. Conclusions Overall this study provided no strong evidence of either causation or prevention of cancer by statins. Copyright (c) 2007 John Wiley & Sons, Ltd.

引用

页码：27 / 36

页数：10

共 36 条

[31] Concomitant medication use in postmenopausal women using estrogen therapy [J].

Small, R ;

Friedman, GD ;

Ettinger, B .

MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2001, 8 (02) :120-126

[32] STUDIES ON THE MECHANISM OF SIMVASTATIN-INDUCED THYROID HYPERTROPHY AND FOLLICULAR CELL ADENOMA IN THE RAT [J].

SMITH, PF ;

GROSSMAN, SJ ;

GERSON, RJ ;

GORDON, LR ;

DELUCA, JG ;

MAJKA, JA ;

WANG, RW ;

GERMERSHAUSEN, JI ;

MACDONALD, JS .

TOXICOLOGIC PATHOLOGY, 1991, 19 (03) :197-205

[33] Lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, induces apoptosis and differentiation in human anaplastic thyroid carcinoma cells [J].

Wang, CY ;

Zhong, WB ;

Chang, TC ;

Lai, SM ;

Tsai, YF .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (07) :3021-3026

[34] HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis [J].

Wong, WWL ;

Dimitroulakos, J ;

Minden, MD ;

Penn, LZ .

LEUKEMIA, 2002, 16 (04) :508-519

[35] Lovastatin suppresses invasiveness of anaplastic thyroid cancer cells by inhibiting Rho geranylgeranylation and RhoA/ROCK signaling [J].

Zhong, WB ;

Liang, YC ;

Wang, CY ;

Chang, TC ;

Lee, WS .

[36] Lovastatin induces apoptosis of anaplastic thyroid cancer cells via inhibition of protein geranylgeranylation and de novo protein synthesis [J].

Zhong, WB ;

Wang, CY ;

Chang, TC ;

Lee, WS .

ENDOCRINOLOGY, 2003, 144 (09) :3852-3859

← 1 2 3 4 →